Bayer is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 million), it said on Thursday. BERLIN, July 14 (Reuters) ...
German chemicals giant Bayer said on Thursday it was selling its male testosterone replacement drug Nebido for up to half-a-billion euros in order to concentrate on medical innovation. The Barron's ...
BERLIN, July 14 (Reuters) - Bayer (BAYGn.DE), opens new tab is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback